Dr. Monath currently serves as Managing Partner and Chief Scientific Officer of Crozet BioPharma LLC. He was formerly Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he led the development of an Ebola virus vaccine in partnership with Merck. Prior to joining NewLink, Dr. Monath held various industry roles at PaxVax Inc., Hookipa Biotech AG, Juvaris Inc., Xcellerex Inc., and Acambis Inc. prior to its acquisition by Sanofi Pasteur. In these roles, he led the development of a broad array of vaccines, including those against influenza, dengue, Japanese encephalitis, West Nile, yellow fever, cytomegalovirus, and smallpox viruses, as well as against Helicobacter pylori and Clostridium difficile; four of these are now licensed.

He is a former partner of the Pandemic and Bio Defense Fund at Kleiner Perkins Caufield & Byers, a leading venture capital firm with a strong life sciences practice. He joined the biotechnology industry following a 20-year career at the U.S. Army Medical Research Institute of Infectious Diseases and the CDC’s Division of Vector-Borne Infectious Diseases. Dr. Monath received his undergraduate and medical degrees at Harvard, was awarded virology fellowships at the University of Ibadan in Ibadan, Nigeria, and at Massachusetts General Hospital in Boston, MA and completed residencies in medicine at Peter Bent Brigham Hospital in Boston.

His published work includes over 425 papers and 6 books in the field of virology and vaccine development.